|
⚲
|
| Keyboard |
| Avidity Partners Management LP
✚
|
|
|---|---|
| CRD # | 304628 |
| SEC # | 801-118809 |
| CIK # | 0001791827 |
| AUM | 1,059.2 M (2026-03-31) |
| Employees | 9 (78% Investors, 0% Brokers) |
| Phone | 214-550-1696 |
| Address | 2828 N Harwood St, Suite 1220 Dallas, TX 75201 |
| Source | [IAPD] [EDGAR] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Magenta Therapeutics Inc | 0.4 | ||
| ARCA Biopharma Inc | 0.1 | ||
| CG Oncology Inc | 0.1 | ||
| Aerovate Therapeutics Inc | 0.1 | ||
| Isoray Inc | 0.0 | ||
| Imara Inc | 0.0 | ||
| Context Therapeutics Inc | 0.0 | ||
| Teva Pharmaceutical Industries Ltd | 0.0 | ||
| Repligen Corp | 0.0 | ||
| Marika Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Avidity Private Master Fund I LP | [2022-03-14] | 169.2 M | 480.3 M |
| Filed 2022-11-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Avidity Master Fund III LP | [2021-03-31] | 30.0 M | |
| Filed 2023-02-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Avidity Capital Fund II LP | [2020-04-27] | 197.9 M | 24.6 M |
| Filed 2024-02-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Avidity Master Fund LP | [2019-10-07] | 1,067.3 M | 554.3 M |
| Filed 2025-09-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 1.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 1.1 |
| By Discretionary | ||
| Discretionary | 7 | 1.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 1.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.0 | |
| United States Persons | 0.0 | |
| Total | 7 | 1.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Georgia Prinsloo | Director | 156 | 37 | |
| Russell Burt | Director | 113 | 29 | |
| Avidity Partners Management LP | Executive Officer | 7 | 2 | |
| Avidity Capital Partners Fund GP LP | Executive Officer | 6 | 2 | |
| Michael Gregory | Director | 6 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001791827] | |
| 3 | [0001791827] | |
| 4 | [0001791827] | |
| SC 13D | [0001791827] | |
| SC 13G | [0001791827] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5493008LOMI55YUT1518 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Dianthus Therapeutics Inc /DE/ | |
| Avidity Partners Management LP | |
| Gregory Michael David | |
| Meng Lei | |
| Witzke David Roy | |
| Avidity Partners Management GP LLC |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Dianthus Therapeutics Inc /DE/ DNTH
Common Stock
|
2024-01-22 | Grant | 1,500,000 | $12.00 | 18,000,000 |
|
Dianthus Therapeutics Inc /DE/ DNTH
Pre-Funded Warrants (Right to Buy) · derivative
|
2024-01-22 | Grant | 1,833,333 | $12.00 | 21,999,996 |
|
Dianthus Therapeutics Inc /DE/ DNTH
Stock Option (Right to Buy) · derivative
|
2023-09-11 | Grant | 6,500 | $0.00 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Upper90 Capital Management LP
✚
|
RI | 1,105.3 M |
|
5AM Venture Management LLC
✚
|
CA | 1,084.3 M |
|
FJ Capital Management LLC
✚
|
VA | 1,079.8 M |
|
Forester Capital LLC
✚
|
CT | 1,070.8 M |
|
Caltius Capital Management LP
✚
|
CA | 1,064.9 M |
|
Preston Capital LLC
✚
|
CA | 1,054.6 M |
|
Whitefort Capital Management LP
✚
|
NY | 1,051.1 M |
|
1543 Capital LP
✚
|
CT | 1,038.0 M |
|
Bay Point Advisors LLC
✚
|
GA | 1,034.0 M |
|
Theorem Partners LLC
✚
|
NY | 1,032.4 M |